Silver Sulfadiazine Cream USP 1%

Manufacturer
Rebel Distributors Corp
Effective date
2012-01-24
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
1
Source
full-release
Hydrated at
2026-05-31 20:14:44

Label at a glance#

ProductSilver Sulfadiazene
Active ingredientSILVER SULFADIAZINE
Label structure10 sections

Indications and uses

Silver Sulfadiazine Cream is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second and third degree burns.

Dosage and administration

FOR TOPICAL USE ONLY - NOT FOR OPHTHALMIC USE: Prompt institution of appropriate regimens for care of the burned patient is of prime importance and includes the control of shock and pain.  The burn wounds are then cleansed and debrided and Silver Sulfadiazine Cream is applied under sterile conditions.  The burn areas should be covered with Silver Sulfadiazine Cream at all times.  The cream should be applied once t...

Label contents#

Full prescribing information#

DESCRPITION

DESCRIPTION SECTION

Silver Sulfadiazine Cream is a topical antibacterial preparation which has its active antimicrobial ingredient silver sulfadiazine. The active moiety is contained within an opaque, white, water miscible cream base.

Each 1000 grams of Silver Sulfadiazine Cream contains 10 grams of silver sulfadiazine.

Inactive Ingrediants: cetyl alcohol, isopropyl myristate, polyoxyl 40 stearate, propylene glycol, purified water, stearyl alcohol, sodium hydroxide, sorbitan monooleate, white petrolatum; with 0.3% methyl paraben, as a preservative.

Silver sulfadiazine has an emprical formula of C10H9AgN4O2S, molecular weight of 357.14 and structural formula as shown:

structural formula of silver sulfadiazine
structural formula of silver sulfadiazine

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Silver sulfadiazine has broad antimicrobial activity.  It is bactericidal for many gram-negative and gram-positive bacteria as well as being effective against yeast.  Results from in vitro testing are listed below. 

Sufficient data have been obtained to demonstrate that silver sulfadiazine will inhibit bacteria that are resistant to other antimicrobial agents and that the compound is superior to sulfadiazine. 

Studies utilizing radioactive micronized silver sulfadiazine, electron microscopy, and biochemical techniques have revealed that the mechanism of action of silver sulfadiazine on bacteria differs from silver nitrate and sodium sulfadiazine.  Silver sulfadiazine acts only on the cell wall to produce its bactericidal effect.


Results of

In Vitro

Testing With Silver Sulfadiazine Cream, 1% Concentration of Silver Sulfadiazine

Number of Sensitive Strains / Total Number of Strains Tested

 Genus and Species      50 µg/mL        100 µ/mL   
 Pseudomonas aeruginosa 130/130 130/130
 Pseudomonas maltophilia 7/7 7/7
 Enterobacter species 48/50 50/50
 Enterobacter cloacae 24/24 24/24
 Klebsiella species 53/54  54/54
 Escherichia coli  63/63 63/63
 Serratia species27/28 28/28
 Proteus mirabilis53/53 53/53
 Morganella morganii10/10 10/10
 Providencia rettgeri  2/22/2 
 Proteus vulgaris 2/22/2 
 Providencia species 1/11/1 
 Citrobacter species 10/1010/10 
 Acinetobacter calcoaceticus 10/1111/11 
 Stahylococcus aureus 100/101101/101
 Staphylococcus epidermidis 51/5151/51 
 β-Hemolytic Streptococcus 4/44/4 
 Enterococcus species  52/5353/53 
 Corynebacterium diphtheriae 2/22/2 
 Clostridium perfringens 0/22/2 
 Candida albicans43/5050/50 

Silver sulfadiazine is not a carbonic anhydrase inhibitor and may be useful in situations where such agents are contraindicated.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Silver Sulfadiazine Cream is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second and third degree burns.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Silver Sulfadiazine Cream is contraindicated in patients who are hypersensitive to silver sulfadiazine or any of the other ingredients in the preparation.

Because sulfonamide therapy is known to increase the possibility of kernicterus, Silver Sulfadiazine Cream should not be used on pregnant women approaching or at term, on premature infants, or on newborn infants during the first 2 months of life.

WARNINGS

WARNINGS SECTION

There is a potential cross sensitivity between silver sulfadiazine and other sulfonamides.  If allergic reactions attributable to treatment with silver sulfadiazine occur, continuation of therapy must be weighed against the potential hazards of the particular allergic reaction.  

Fungal proliferation in and below the eschar may occur.  However, the incidence of clinically reported fungal superinfection is low.

The use of Silver Sulfadiazine Cream in some cases of glucose-6-phosphate dehydrogenase-deficient individuals may be hazardous, as hemolysis may occur.

PRECAUTION

PRECAUTIONS SECTION

General

GENERAL PRECAUTIONS SECTION

If hepatic and renal functions become impaired and elimination of the drug decreases, accumulation may occur and discontinuation of Silver Sulfadiazine Cream should be weighed against the therapeutic benefit being achieved.

In considering the use of topical proteolytic enzymes in conjunction with Silver Sulfadiazine Cream, the possibility should be noted that silver may inactivate such enzymes.

Laboratory Tests

LABORATORY TESTS SECTION

In the treatment of burn wounds involving extensive areas of the body, the serum sulfa concentrations may approach adult therapeutic levels (8 to 12 mg %).  Therefore, in these patients it would be advisable to monitor serum sulfa concentrations.  Renal function should be carefully monitored and the urine should be checked for sulfa crystals. 

Absorption of the propylene glycol vehicle has been reported to affect serum osmolality, which may affect the interpretation of laboratory tests.

Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Long-term dermal toxicity studies of 24 months duration in rats and 18 months in mice with concentrations of silver sulfadiazine three to ten times the concentration in Silver Sulfadiazine Cream revealed no evidence of carcinogenicity.

Pregnancy

PREGNANCY SECTION

Pregnancy category B. A reproductive study has been performed in rabbits at doses up to three to ten times the concentration of silver sulfadiazine in Silver Sulfadiazine Cream and has revealed no evidence of harm to the fetus due to silver sulfadiazine.  There are, however, no adequate and well controlled studies in pregnant women.  Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly justified, especially in pregnant women approaching or at term (See CONTRAINDICATIONS).

Nursing Mothers

NURSING MOTHERS SECTION

It is not known whether Silver Sulfadiazine Cream is excreted in human milk.  However, sulfonamides are known to be excreted in human milk and all sulfonamides derivatives are known to increase the possibility of kernicterus.  Because of the potential for serious adverse reactions in nursing infants from sulfonamides, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use

PEDIATRIC USE SECTION

Safety and effectiveness in children have not been established (See CONTRAINDICATIONS).

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Several cases of transient leucopenia have been reported in patients receiving silver sulfadiazine therapy.  Leucopenia associated with silver sulfadiazine administration is primarily characterized by decreased neutrophil count.  Maximal white blood cell depression occurs within two to four days of initiation of therapy.  Rebound to normal leukocyte levels follows onset within two to three days.  Recovery is not influenced by continuation of silver sulfadiazine therapy.  The incidence of leucopenia in various reports averages about 20%.  A higher incidence has been seen in patients treated concurrently with cimetidine.

Other infrequently occurring events include skin necrosis, erythema multiforme, skin discoloration, burning sensation, rashes, and interstitial nephritis.  Reduction in bacterial growth after application of topical antibacterial agents has been reported to permit spontaneous healing of deep partial-thickness burns by preventing conversion of the partial thickness to full thickness by sepsis.  However, reduction in bacterial colonization has caused delayed separation, in some cases necessitating escharotomy in order to prevent contracture.

Absorption of silver sulfadiazine varies depending upon the percent of body surface area and the extent of the tissue damage.  Although few have been reported, it is possible that any adverse reaction associated with sulfonamides may occur.  Some of the reactions which have been associated with sulfonamides are as follows: blood dyscrasias, including agranulocytosis, aplastic anemia, thrombocytopenia, leucopenia, hemolytic anemia; dermatologic and allergic reactions, Stevens-Johnson syndrome and exfoliative dermatitis; gastrointestinal reactions; hepatitis and hepatocellular necrosis; CNS reactions; and toxic nephrosis.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

FOR TOPICAL USE ONLY - NOT FOR OPHTHALMIC USE: Prompt institution of appropriate regimens for care of the burned patient is of prime importance and includes the control of shock and pain.  The burn wounds are then cleansed and debrided and Silver Sulfadiazine Cream is applied under sterile conditions.  The burn areas should be covered with Silver Sulfadiazine Cream at all times.  The cream should be applied once to twice daily to a thickness of approximately 1/16 inch.  Whenever necessary, the cream should be reapplied to any areas from which it has been removed due to patient activity.  Administration may be accomplished in minimal time because dressings are not required.  However, if individual patient requirements make dressings necessary, they may be used. 

Reapply immediately after hydrotherapy. 

Treatment with Silver Sulfadiazine Cream should be continued until satisfactory healing has occurred or until the burn site is ready for grafting.  The drug should not be withdrawn from the therapeutic regimen while there remains the possibility of infection except if a significant adverse reaction occurs.

HOW SUPPLIED

HOW SUPPLIED SECTION

Silver Sulfadiazine Cream USP 1%: white to off-white cream.

25 gram tube                     

Store at controlled room temperature 15°-30°C (59°-86°F).

Manufactured for
Watson Laboratories, Inc.
Corona, CA 92880 USA
Manufactured by
Dr. Reddy's Laboratories Louisiana, LLC
Shreveport, LA 71106
R05/08       110960-02

Repackaged by:
Rebel Distributors Corp
Thousand Oaks, CA 91320

PRINCIPAL DISPLAY PANEL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Silver Sulfadiazine 1%
Silver Sulfadiazine 1%

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
106351silver sulfADIAZINE 1 % Topical CreamPSN1
106351silver sulfadiazine 10 MG/ML Topical CreamSCD1
106351silver sulfadiazine 1 % Topical CreamSY1

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
SILVER SULFADIAZINE Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
6cca4355-1206-91f7-02de-17eef38a8622Product name120140508
751c581a-bf64-2fd7-b3ec-ca02c83e4a00Product name120140508

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDCEffectiveActionDocumentIndexing SPLRelated label
42254-118-252019-09-24C16284748780-19350213a-3e18-c013-e053-90daa90a1393Silver Sulfadiazine Cream USP 1%

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
42254-118-25Silver Sulfadiazene25 g in 1 TUBECREAM251

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
42254-118SILVER SULFADIAZENE (SILVER SULFADIAZINE) CREAM [REBEL DISTRIBUTORS CORP]1Legacy NDC, 1 package rows20120411_b03ca090-40fe-44b0-838a-69aed3424a06.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
42254-118-25GM - Gram42254-118b7bc5f4a-6333-4b47-a24b-0b4cc935671b12012-07-24
0591-0810-46GM - Gram0591-0810cd3b3b95-f135-4610-8240-92faddbae0e912012-07-24
0591-0810-55GM - Gram0591-08108793ecb3-3e64-4803-8cb4-35408fd2e1f212012-07-24
0591-0810-83GM - Gram0591-08103895fb01-d2a0-4df7-8422-ccf8b5aac89712012-07-24
0591-0810-85GM - Gram0591-0810d661cd6d-d087-458e-a5d9-b49bc7ed2c8e12012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
SILVER SULFADIAZINEACTIVE INGREDIENTW46JY43EJR1
SILVER SULFADIAZINEACTIVE MOIETYW46JY43EJR1
CETYL ALCOHOLINACTIVE INGREDIENT936JST6JCN1
ISOPROPYL MYRISTATEINACTIVE INGREDIENT0RE8K4LNJS1
METHYLPARABENINACTIVE INGREDIENTA2I8C7HI9T1
PETROLATUMINACTIVE INGREDIENT4T6H12BN9U1
POLYOXYL 40 STEARATEINACTIVE INGREDIENT13A4J4NH9I1
PROPYLENE GLYCOLINACTIVE INGREDIENT6DC9Q167V31
SODIUM HYDROXIDEINACTIVE INGREDIENT55X04QC32I1
SORBITAN MONOOLEATEINACTIVE INGREDIENT06XEA2VD561
STEARYL ALCOHOLINACTIVE INGREDIENT2KR89I4H1Y1
WATERINACTIVE INGREDIENT059QF0KO0R1

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 12 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
42254-11842254-118-25
0591-0810

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 11 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 8 · 431 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
METHYLPARABENMETHYLPARABENA2I8C7HI9TOINTMENT / OPHTHALMIC0.05 %w/wExact identifier — unii candidate
79 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SUSPENSION, LIPOSOMAL / INTRAVENOUSADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
CETYL ALCOHOLCETYL ALCOHOL936JST6JCNAEROSOL, FOAM / TOPICAL82 mgExact identifier — unii candidate
20 equally ranked IID candidates
PETROLATUMPETROLATUM4T6H12BN9USPONGE / TOPICALNAExact identifier — unii candidate
18 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3GEL / VAGINAL750 mgExact identifier — unii candidate
81 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IFILM / BUCCAL0.09 mgExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SUSPENSION / INTRA-ARTICULARADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TINJECTION, SOLUTION / PARENTERAL30 mgExact identifier — unii candidate
79 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISPRAY, METERED / NASALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION / IRRIGATIONADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ICREAM, AUGMENTED / TOPICAL6 mgExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / ENDOTRACHEALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION/ DROPS / OPHTHALMICADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
STEARYL ALCOHOLSTEARYL ALCOHOL2KR89I4H1YPOWDER / ORAL0.11 mgExact identifier — unii candidate
12 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / INTRASYNOVIALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SORBITAN MONOOLEATESORBITAN MONOOLEATE06XEA2VD56SYSTEM / TRANSDERMAL2.33 mgExact identifier — unii candidate
16 equally ranked IID candidates
SORBITAN MONOOLEATESORBITAN MONOOLEATE06XEA2VD56OINTMENT / TOPICALNAExact identifier — unii candidate
16 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IELIXIR / ORALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3CLOTH / TOPICAL0.03 mg/mgExact identifier — unii candidate
81 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION / RESPIRATORY (INHALATION)8 %w/vExact identifier — unii candidate
174 equally ranked IID candidates
ISOPROPYL MYRISTATEISOPROPYL MYRISTATE0RE8K4LNJSOINTMENT / TOPICAL35 %w/wExact identifier — unii candidate
18 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SOLUTION / INTRACAUDALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SORBITAN MONOOLEATESORBITAN MONOOLEATE06XEA2VD56CREAM / TOPICAL11000 mgExact identifier — unii candidate
16 equally ranked IID candidates
CETYL ALCOHOLCETYL ALCOHOL936JST6JCNSUSPENSION / TOPICAL2.01 %w/wExact identifier — unii candidate
20 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRA-ARTERIALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTABLE, LIPOSOMAL / INTRAVENOUSADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISUSPENSION, EXTENDED RELEASE / INTRA-ARTICULARADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
POLYOXYL 40 STEARATEPOLYOXYL 40 STEARATE TYPE I13A4J4NH9ISUSPENSION / AURICULAR (OTIC)1 %w/vExact identifier — unii candidate
13 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TJELLY / TOPICAL420 mgExact identifier — unii candidate
79 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3TAMPON / VAGINAL62.1 mgExact identifier — unii candidate
81 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TPOWDER, FOR SUSPENSION / ORAL75 mgExact identifier — unii candidate
79 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TCONCENTRATE / ORAL12 mgExact identifier — unii candidate
79 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3TABLET, FILM COATED / ORAL96 mgExact identifier — unii candidate
81 equally ranked IID candidates
SORBITAN MONOOLEATESORBITAN MONOOLEATE06XEA2VD56TABLET, FILM COATED, EXTENDED RELEASE / ORAL2 mgExact identifier — unii candidate
16 equally ranked IID candidates
CETYL ALCOHOLCETYL ALCOHOL936JST6JCNTABLET, FILM COATED / ORALNAExact identifier — unii candidate
20 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IEMULSION / TOPICAL0.2 %w/wExact identifier — unii candidate
174 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3TABLET, FILM COATED, EXTENDED RELEASE / ORAL19 mgExact identifier — unii candidate
81 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, POWDER, FOR SOLUTION / PARENTERALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISPONGE / TOPICALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ILIQUID / TOPICALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION, CONCENTRATE / INTRAVENOUSADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IOINTMENT / TOPICALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3OINTMENT / RECTAL27 mgExact identifier — unii candidate
81 equally ranked IID candidates
POLYOXYL 40 STEARATEPOLYOXYL 40 STEARATE TYPE I13A4J4NH9ICREAM / TOPICAL86000 mgExact identifier — unii candidate
13 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ITABLET / ORAL10 mgExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SOLUTION / INTRATHECALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION / URETERALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SOLUTION / INTRAVENOUS78 mgExact identifier — unii candidate
174 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TSHAMPOO / TOPICAL0.15 %w/wExact identifier — unii candidate
79 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SOLUTION / INTRAVESICALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SORBITAN MONOOLEATESORBITAN MONOOLEATE06XEA2VD56TABLET, DELAYED RELEASE / ORAL4 mgExact identifier — unii candidate
16 equally ranked IID candidates
SORBITAN MONOOLEATESORBITAN MONOOLEATE06XEA2VD56EMULSION / TOPICAL34050 mgExact identifier — unii candidate
16 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TSUPPOSITORY / VAGINALNAExact identifier — unii candidate
79 equally ranked IID candidates
POLYOXYL 40 STEARATEPOLYOXYL 40 STEARATE TYPE I13A4J4NH9IOINTMENT / TOPICALNAExact identifier — unii candidate
13 equally ranked IID candidates
POLYOXYL 40 STEARATEPOLYOXYL 40 STEARATE TYPE I13A4J4NH9ILOTION / TOPICAL3 %w/wExact identifier — unii candidate
13 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SOLUTION / INTRA-ARTICULARADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
ISOPROPYL MYRISTATEISOPROPYL MYRISTATE0RE8K4LNJSCREAM / VAGINAL50 mgExact identifier — unii candidate
18 equally ranked IID candidates
POLYOXYL 40 STEARATEPOLYOXYL 40 STEARATE TYPE I13A4J4NH9IGRANULE / ORALNAExact identifier — unii candidate
13 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3SHAMPOO, SUSPENSION / TOPICAL2 %w/wExact identifier — unii candidate
81 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / PERINEURALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 2 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N018578-001SSDSILVER SULFADIAZINE1%CREAM / TOPICALABRLD, RS1982-02-25
N018578-003SSD AFSILVER SULFADIAZINE1%CREAM / TOPICAL1990-07-11

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
N018578-001AB

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 3 · 86 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08N018578-001SSD1%CREAM / TOPICALABRLD, RS1982-02-2584e616aacf4f…
2026-09-14 22:38:342026-08N018578-003SSD AF1%CREAM / TOPICAL1990-07-1184e616aacf4f…
2026-08-18 06:07:402026-07N018578-001SSD1%CREAM / TOPICALABRLD, RS1982-02-25caaa826d4ba7…
2026-08-18 06:07:402026-07N018578-003SSD AF1%CREAM / TOPICAL1990-07-11caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N018578-001SSD1%CREAM / TOPICALABRLD, RS1982-02-25011fe1cb6892…
2026-02-19 14:30 UTC2026-02N018578-003SSD AF1%CREAM / TOPICAL1990-07-11011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N018578-001SSD1%CREAM / TOPICALABRLD, RS1982-02-2531067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N018578-003SSD AF1%CREAM / TOPICAL1990-07-1131067a03dcf5…
2025-08-23 18:47 UTC2025-08N018578-001SSD1%CREAM / TOPICALABRLD, RS1982-02-256a471c1ec25d…
2025-08-23 18:47 UTC2025-08N018578-003SSD AF1%CREAM / TOPICAL1990-07-116a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N018578-001SSD1%CREAM / TOPICALABRLD, RS1982-02-25fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N018578-003SSD AF1%CREAM / TOPICAL1990-07-11fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N018578-001SSD1%CREAM / TOPICALABRLD, RS1982-02-25b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N018578-003SSD AF1%CREAM / TOPICAL1990-07-11b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N018578-001SSD1%CREAM / TOPICALABRLD, RS1982-02-2503ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N018578-003SSD AF1%CREAM / TOPICAL1990-07-1103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N018578-001SSD1%CREAM / TOPICALABRLD, RS1982-02-252680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N018578-003SSD AF1%CREAM / TOPICAL1990-07-112680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N018578-001SSD1%CREAM / TOPICALABRLD, RS1982-02-255bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N018578-003SSD AF1%CREAM / TOPICAL1990-07-115bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N018578-001SSD1%CREAM / TOPICALABRLD, RS1982-02-25d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N018578-003SSD AF1%CREAM / TOPICAL1990-07-11d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N018578-001SSD1%CREAM / TOPICALABRLD, RS1982-02-25d06236e962d9…
2024-10-29 15:01 UTC2024-10N018578-003SSD AF1%CREAM / TOPICAL1990-07-11d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N018578-001SSD1%CREAM / TOPICALABRLD, RS1982-02-2579d66fd596c7…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N018578-003SSD AF1%CREAM / TOPICAL1990-07-1179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N018578-001SSD1%CREAM / TOPICALABRLD, RS1982-02-25301d65b070ca…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N018578-003SSD AF1%CREAM / TOPICAL1990-07-11301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N018578-001SSD1%CREAM / TOPICALABRLD, RS1982-02-251e350fbaab3a…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N018578-003SSD AF1%CREAM / TOPICAL1990-07-111e350fbaab3a…
2024-05-31 18:47 UTC2024-05N018578-001SSD1%CREAM / TOPICALABRLD, RS1982-02-258072bd15b7f6…
2024-05-31 18:47 UTC2024-05N018578-003SSD AF1%CREAM / TOPICAL1990-07-118072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N018578-001SSD1%CREAM / TOPICALAB1982-02-255c6f7cd8ea54…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N018578-003SSD AF1%CREAM / TOPICAL1990-07-115c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N018578-001SSD1%CREAM / TOPICALAB1982-02-255d02ea3f76ae…
2022-04-08 23:34 UTC2022-04N018578-003SSD AF1%CREAM / TOPICAL1990-07-115d02ea3f76ae…
2022-04-04 05:41 UTC2022-04N018578-001SSD1%CREAM / TOPICALAB1982-02-254b0b4de00fa7…
2022-04-04 05:41 UTC2022-04N018578-003SSD AF1%CREAM / TOPICAL1990-07-114b0b4de00fa7…
2019-12-13 00:20 UTC2019-12N018578-001SSD1%CREAM / TOPICALAB1982-02-2574a2ff9319b5…
2019-12-13 00:20 UTC2019-12N018578-003SSD AF1%CREAM / TOPICAL1990-07-1174a2ff9319b5…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-09-14 22:38:342026-08N018578-001AB184e616aacf4f…
2026-08-18 06:07:402026-07N018578-001AB1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N018578-001AB1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N018578-001AB131067a03dcf5…
2025-08-23 18:47 UTC2025-08N018578-001AB16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N018578-001AB1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N018578-001AB1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N018578-001AB103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N018578-001AB12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N018578-001AB15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N018578-001AB1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N018578-001AB1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N018578-001AB179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N018578-001AB1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N018578-001AB11e350fbaab3a…
2024-05-31 18:47 UTC2024-05N018578-001AB18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N018578-001AB15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N018578-001AB15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04N018578-001AB14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12N018578-001AB174a2ff9319b5…
2022-03-09 01:35 UTC2022-03N018578-001AB1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12N018578-001AB1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05N018578-001AB187673890dc5c…
2021-03-12 10:30 UTC2021-03N018578-001AB15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12N018578-001AB18869cabd3fbd…
2020-11-12 02:37 UTC2020-11N018578-001AB1c0c555d07b60…
2019-12-14 00:12 UTC2019-12N018578-001AB13f01610625f2…
2019-09-15 20:21 UTC2019-09N018578-001AB1b00525d2431f…
2019-07-19 19:46 UTC2019-07N018578-001AB1ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03N018578-001AB16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02N018578-001AB11c564ffb4f44…
2023-12-20 04:57 UTC2023-12N018578-001AB1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11N018578-001AB1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10N018578-001AB19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07N018578-001AB1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06N018578-001AB13f0d92c62455…
2023-05-13 08:27 UTC2023-05N018578-001AB1053a50430f4f…
2023-01-26 05:58 UTC2023-01N018578-001AB13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11N018578-001AB13a93d1ddd44b…
2022-10-28 04:53 UTC2022-10N018578-001AB1f41ea6bd6efb…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
b03ca090-40fe-44b0-838a-69aed3424a06b03ca090-40fe-44b0-838a-69aed3424a062012-01-24Warnings, Adverse reactionsExact identifier
spl id: b03ca090-40fe-44b0-838a-69aed3424a06
spl set id: b03ca090-40fe-44b0-838a-69aed3424a06

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.